Vivani Medical Inc (VANI)
Vivani Medical Inc is a clinical-stage biopharmaceutical company listed on the NASDAQ under the symbol VANI. The company is developing miniaturized subdermal drug-implant technologies designed to support treatment of chronic diseases and address medication non-adherence. Its NanoPortal platform underpins a pipeline that includes NPM-115, a high-dose exenatide implant candidate in clinical development for chronic weight management in people with obesity or overweight; NPM-119, an exenatide implant candidate in preclinical development for type 2 diabetes; NPM-139, a small GLP-1 implant for weight management; and OKV-119, an exenatide implant being developed for metabolic disease in cats. Vivani Medical is headquartered in Alameda, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VANI
|
$1.02
|
-28.1% Downside
|
Overvalued
|
$3.83
|
170.0% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 18, 2026
|
-4.5x
|
6.4x
|
—
|
116.4 M
|
121.4 M
|
13.6%
|
40.5%
|
-3.9
|
—
|
97.9%
|
